好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Neuropathy with Autoantibodies Against Septin Multimers in PNS Myelin Mimicking Lower Motor Neuron Disease
Neuromuscular and Clinical Neurophysiology (EMG)
P4 - Poster Session 4 (5:00 PM-6:00 PM)
11-028

Severe neuropathies with predominant affection of motor fibers can mimic lower motor neuron disease (LMND) phenotypes such as in motor predominant chronic inflammatory demyelinating polyradiculoneuropathy and bulbar anti-IgLON5 disease. Given the fatal prognosis of LMND, identifying underlying autoimmune syndromes is crucial to provide treatment options to patients.

NA

Consecutive patients’ sera (n=2266, referred for antineuronal antibody testing, collected over one year) were tested for IgG reactivity against nervous system tissues. A novel binding pattern on murine teased fibers was further investigated by target identification using immunoprecipitation coupled to mass-spectrometry. Target specificity of these autoantibodies was validated in cell-based assays, neutralization assays, and knock-out models. A retrospective study cohort consisting of healthy controls (n=50), disease controls (n=50 amyotrophic lateral sclerosis, n=50 multiple sclerosis), and patients with neuropathies and similar IgG reactivity on teased fibers (n=27) were screened for presence of anti-septin multimer autoantibodies. Histopathological analysis of skin and sural nerve in one seropositive patient was performed, and antibody binding was characterized in vitro. Immunotherapy was initiated, with clinical and serological follow-up over three years.

Two patients initially diagnosed with LMND showed a novel pattern on peripheral nerves, binding to Schmidt-Lanterman incisures (SLIs), paranodes, and abaxonal myelin. Target identification revealed septin multimers as autoantibody epitopes. In living myelinated dorsal root ganglia cells, binding of autoreactive IgGs was evident primarily at SLIs (“incisuropathy”), and septin multimer IgGs initiated complement deposition on cell-based assays. Sural nerve and skin biopsies showed inflammation, myelin predominant pathology, and morphological alterations of SLIs. Immunotherapy in one patient led to stabilization, while the other untreated patient deceased two years after symptom onset.

Our data suggest that septin multimer autoimmunity can occur in severe motor predominant neuropathies, initially mimicking lower motor neuron disease. Screening for anti-septin multimer IgGs with consequent immunotherapy initiation in seropositive cases should be considered in LMND.


Authors/Disclosures
Friederike A. Arlt, MD
PRESENTER
Dr. Arlt has nothing to disclose.
Ramona Miske Ramona Miske has received personal compensation for serving as an employee of Euroimmun. Ramona Miske has received intellectual property interests from a discovery or technology relating to health care.
Luise Appeltshauser, MD Dr. Appeltshauser has nothing to disclose.
Kathrin Borowski Mrs. Borowski has nothing to disclose.
Divyanshu Dubey, MD, FAAN (Mayo Clinic) The institution of Dr. Dubey has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Argenx. The institution of Dr. Dubey has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Arialys. The institution of Dr. Dubey has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB . Dr. Dubey has received research support from Department of Defense . Dr. Dubey has received research support from Department of Defense . Dr. Dubey has received research support from UCB. Dr. Dubey has received research support from David J. Tomassoni ALS Research Grant Program . Dr. Dubey has received intellectual property interests from a discovery or technology relating to health care. Dr. Dubey has received intellectual property interests from a discovery or technology relating to health care. Dr. Dubey has received intellectual property interests from a discovery or technology relating to health care. Dr. Dubey has received intellectual property interests from a discovery or technology relating to health care.
Werner Stenzel, MD Prof. Stenzel has nothing to disclose.
Helena Radbruch, MD The institution of Dr. Radbruch has received research support from German Research Foundation (DFG).
Andreas Meisel (Charité Universitätsmedizin Berlin) Andreas Meisel has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Alexion. Andreas Meisel has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for argenx. Andreas Meisel has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Adivo. Andreas Meisel has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Janssen. Andreas Meisel has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB. Andreas Meisel has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Andreas Meisel has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for argenx. The institution of Andreas Meisel has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB. Andreas Meisel has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck. Andreas Meisel has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Alexion. Andreas Meisel has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for argenx. Andreas Meisel has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for UCB. Andreas Meisel has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis. Andreas Meisel has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Sanofi. Andreas Meisel has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Pfizer/BMS. Andreas Meisel has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Boehringer. Andreas Meisel has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Axunio. Andreas Meisel has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Desitin. Andreas Meisel has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Genpharm. The institution of Andreas Meisel has received research support from Alexion. The institution of Andreas Meisel has received research support from argenx. The institution of Andreas Meisel has received research support from Octapharma. The institution of Andreas Meisel has received research support from Deutsche Myasthenie Gesellschaft. The institution of Andreas Meisel has received research support from Deutsche Forschungsgemeinschaft . The institution of Andreas Meisel has received research support from Bundesministerium für Wissenschaft und Forschung. The institution of Andreas Meisel has received research support from Leducq Foundation. The institution of Andreas Meisel has received research support from Einstein Stiftung Berlin. Andreas Meisel has received publishing royalties from a publication relating to health care. Andreas Meisel has received publishing royalties from a publication relating to health care. Andreas Meisel has a non-compensated relationship as a Chairman, Medical Advisory Board with Deutsche Myasthenie Gesellschaft that is relevant to AAN interests or activities. Andreas Meisel has a non-compensated relationship as a Chairman with Berliner Schlaganfall Gesellschaft that is relevant to AAN interests or activities.
Klemens Ruprecht, MD (Klinik fur Neurologie) Dr. Ruprecht has received research support from European Union (821283-2). Dr. Ruprecht has received research support from Merck Serono. Dr. Ruprecht has received research support from Stiftung Charite. Dr. Ruprecht has received research support from Arthur Arnstein Foundation. Dr. Ruprecht has received publishing royalties from a publication relating to health care.
Matthias Endres, MD The institution of Prof. Endres has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bayer. The institution of Prof. Endres has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for BMS. The institution of Prof. Endres has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Bayer. The institution of Prof. Endres has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for AstraZeneca. The institution of Prof. Endres has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Daiichi Sankyo. The institution of Prof. Endres has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amgen. The institution of Prof. Endres has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Bayer. The institution of Prof. Endres has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Amgen. Prof. Endres has received personal compensation in the range of $5,000-$9,999 for serving as a clinical coordination Berlin site with DZNE.
Marieluise Kirchner, PhD Ms. Kirchner has nothing to disclose.
Philipp Mertins, PhD Dr. Mertins has nothing to disclose.
Elisa Sanchez-Sendin, PhD Dr. Sanchez-Sendin has nothing to disclose.
Stephanie Wernick Mrs. Wernick has nothing to disclose.
Sophie Hümmert Ms. Hümmert has nothing to disclose.
Hauke B. Werner Prof. Werner has nothing to disclose.
Kathrin Doppler, MD Dr. Doppler has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Takeda. Dr. Doppler has received personal compensation in the range of $500-$4,999 for serving as a Presenter with Roche. Dr. Doppler has received personal compensation in the range of $500-$4,999 for serving as a Presenter with Grifols. Dr. Doppler has received personal compensation in the range of $500-$4,999 for serving as a Presenter with Sanofi.
Lars Komorowski Lars Komorowski has received personal compensation in the range of $100,000-$499,999 for serving as an officer or member of the Board of Directors for EUROIMMUN . Lars Komorowski has stock in Revvity. Lars Komorowski has received intellectual property interests from a discovery or technology relating to health care.
Andrew McKeon, MD (Mayo Clinic) The institution of Dr. McKeon has received research support from National Institutes of Health. Dr. McKeon has received intellectual property interests from a discovery or technology relating to health care. Dr. McKeon has received intellectual property interests from a discovery or technology relating to health care. Dr. McKeon has received publishing royalties from a publication relating to health care.
Madeleine Scharf, PhD Dr. Scharf has received personal compensation for serving as an employee of Euroimmun AG.
Harald Pruss Harald Pruss has nothing to disclose.